Tobramycin is an aminoglycoside antibiotic ... treatment is the FDA approvals of fourth-generation fluoroquinolones Vigamox and Zymar. These approvals come at a time when the newest ...

Tobramycin in external eye disease ... comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial ...

The activity, pharmacokinetics, pharmacodynamics, efficacy, safety, drug interactions, and dosage and administration of moxifloxacin are reviewed. Moxifloxacin is an oral 8-methoxyquinolone ...

It alerts doctors and patients about drug effects that may be dangerous. Moxifloxacin oral tablet is available as a brand-name drug and a generic drug. Brand name: Avelox. Moxifloxacin comes as a ...

she had also been started on a regimen of intravenous tobramycin and imipenem and oral clarithromycin. She took these antibiotics for 6 weeks before switching to oral moxifloxacin and clarithromycin.

Moxifloxacin is currently approved in more than 100 countries, including the United States, as a treatment for bacterial respiratory infections, such as bronchitis, sinusitis and pneumonia. Share ...

Moxifloxacin (as HCl) 400mg/250mL; soln for IV infusion; latex- and preservative-free. Moxifloxacin inhibits topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial ...

The study met the primary and secondary endpoints, showing that omadacycline is non-inferior to moxifloxacin for the treatment of CABP. Paratek announced positive top-line data from the global ...

Moxifloxacin's 5-day treatment course for acute bacterial exacerbations of chronic bronchitis is shorter than the 7- to 10-day course suggested for other fluoroquinolones with this indication.